vs
Side-by-side financial comparison of Arlo Technologies, Inc. (ARLO) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Arlo Technologies, Inc. is the larger business by last-quarter revenue ($141.3M vs $92.9M, roughly 1.5× Vericel Corp). Vericel Corp runs the higher net margin — 25.0% vs 4.1%, a 20.9% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 16.2%). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 6.7%).
Arlo Technologies is an American company that makes wireless surveillance cameras. Prior to an initial public offering (IPO) on the New York Stock Exchange in August 2018, Arlo was a brand of such products by Netgear, which retained majority control after the IPO.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
ARLO vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $141.3M | $92.9M |
| Net Profit | $5.8M | $23.2M |
| Gross Margin | 46.4% | 78.7% |
| Operating Margin | 3.3% | 24.1% |
| Net Margin | 4.1% | 25.0% |
| Revenue YoY | 16.2% | 23.3% |
| Net Profit YoY | 218.6% | 17.3% |
| EPS (diluted) | $0.06 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $141.3M | $92.9M | ||
| Q3 25 | $139.5M | $67.5M | ||
| Q2 25 | $129.4M | $63.2M | ||
| Q1 25 | $119.1M | $52.6M | ||
| Q4 24 | $121.6M | $75.4M | ||
| Q3 24 | $137.7M | $57.9M | ||
| Q2 24 | $127.4M | $52.7M | ||
| Q1 24 | $124.2M | $51.3M |
| Q4 25 | $5.8M | $23.2M | ||
| Q3 25 | $6.9M | $5.1M | ||
| Q2 25 | $3.1M | $-553.0K | ||
| Q1 25 | $-835.0K | $-11.2M | ||
| Q4 24 | $-4.9M | $19.8M | ||
| Q3 24 | $-4.4M | $-901.0K | ||
| Q2 24 | $-11.6M | $-4.7M | ||
| Q1 24 | $-9.6M | $-3.9M |
| Q4 25 | 46.4% | 78.7% | ||
| Q3 25 | 40.5% | 73.5% | ||
| Q2 25 | 44.9% | 73.7% | ||
| Q1 25 | 44.3% | 69.0% | ||
| Q4 24 | 36.9% | 77.6% | ||
| Q3 24 | 35.2% | 71.9% | ||
| Q2 24 | 36.8% | 69.5% | ||
| Q1 24 | 38.1% | 68.9% |
| Q4 25 | 3.3% | 24.1% | ||
| Q3 25 | 0.6% | 5.1% | ||
| Q2 25 | 1.5% | -3.2% | ||
| Q1 25 | -1.2% | -24.3% | ||
| Q4 24 | -5.0% | 24.5% | ||
| Q3 24 | -4.0% | -4.3% | ||
| Q2 24 | -10.0% | -11.5% | ||
| Q1 24 | -8.5% | -10.7% |
| Q4 25 | 4.1% | 25.0% | ||
| Q3 25 | 4.9% | 7.5% | ||
| Q2 25 | 2.4% | -0.9% | ||
| Q1 25 | -0.7% | -21.4% | ||
| Q4 24 | -4.0% | 26.3% | ||
| Q3 24 | -3.2% | -1.6% | ||
| Q2 24 | -9.1% | -8.9% | ||
| Q1 24 | -7.8% | -7.5% |
| Q4 25 | $0.06 | $0.46 | ||
| Q3 25 | $0.06 | $0.10 | ||
| Q2 25 | $0.03 | $-0.01 | ||
| Q1 25 | $-0.01 | $-0.23 | ||
| Q4 24 | $-0.05 | $0.40 | ||
| Q3 24 | $-0.04 | $-0.02 | ||
| Q2 24 | $-0.12 | $-0.10 | ||
| Q1 24 | $-0.10 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $146.4M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $127.8M | $354.6M |
| Total Assets | $310.5M | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $146.4M | $137.5M | ||
| Q3 25 | $86.0M | $135.4M | ||
| Q2 25 | $71.2M | $116.9M | ||
| Q1 25 | $84.0M | $112.9M | ||
| Q4 24 | $82.0M | $116.2M | ||
| Q3 24 | $77.0M | $101.7M | ||
| Q2 24 | $62.9M | $102.5M | ||
| Q1 24 | $62.1M | $110.6M |
| Q4 25 | $127.8M | $354.6M | ||
| Q3 25 | $129.2M | $321.9M | ||
| Q2 25 | $118.3M | $306.8M | ||
| Q1 25 | $103.4M | $295.5M | ||
| Q4 24 | $100.9M | $292.0M | ||
| Q3 24 | $96.9M | $257.5M | ||
| Q2 24 | $99.3M | $243.0M | ||
| Q1 24 | $99.9M | $233.9M |
| Q4 25 | $310.5M | $488.0M | ||
| Q3 25 | $350.9M | $453.3M | ||
| Q2 25 | $319.7M | $435.6M | ||
| Q1 25 | $296.6M | $424.6M | ||
| Q4 24 | $298.4M | $432.7M | ||
| Q3 24 | $312.4M | $390.4M | ||
| Q2 24 | $295.8M | $376.8M | ||
| Q1 24 | $289.8M | $356.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.8M | $15.0M |
| Free Cash FlowOCF − Capex | — | $12.8M |
| FCF MarginFCF / Revenue | — | 13.8% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | 3.43× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.8M | $15.0M | ||
| Q3 25 | $19.2M | $22.1M | ||
| Q2 25 | $8.8M | $8.2M | ||
| Q1 25 | $30.9M | $6.6M | ||
| Q4 24 | $6.7M | $22.2M | ||
| Q3 24 | $18.4M | $10.2M | ||
| Q2 24 | $6.5M | $18.5M | ||
| Q1 24 | $19.8M | $7.2M |
| Q4 25 | — | $12.8M | ||
| Q3 25 | — | $19.5M | ||
| Q2 25 | — | $81.0K | ||
| Q1 25 | $28.1M | $-7.6M | ||
| Q4 24 | $5.6M | $8.5M | ||
| Q3 24 | $17.4M | $-9.2M | ||
| Q2 24 | $6.2M | $1.8M | ||
| Q1 24 | $19.4M | $-6.8M |
| Q4 25 | — | 13.8% | ||
| Q3 25 | — | 28.8% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | 23.6% | -14.5% | ||
| Q4 24 | 4.6% | 11.2% | ||
| Q3 24 | 12.6% | -15.9% | ||
| Q2 24 | 4.8% | 3.4% | ||
| Q1 24 | 15.7% | -13.3% |
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | 2.4% | 27.0% | ||
| Q4 24 | 0.9% | 18.3% | ||
| Q3 24 | 0.7% | 33.5% | ||
| Q2 24 | 0.2% | 31.8% | ||
| Q1 24 | 0.3% | 27.3% |
| Q4 25 | 3.43× | 0.65× | ||
| Q3 25 | 2.79× | 4.35× | ||
| Q2 25 | 2.83× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ARLO
| Subscriptions And Services | $89.4M | 63% |
| Products | $51.9M | 37% |
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
